Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript

Author index

Page Path
HOME > Browse articles > Author index
Jin-Oh Choi 1 Article
Tafamidis for Cardiac Transthyretin Amyloidosis
Darae Kim, Jin-Oh Choi, Eun-Seok Jeon
Cardiovasc Prev Pharmacother. 2021;3(1):1-9.   Published online January 31, 2021
  • 4,825 View
  • 73 Download
  • 2 Citations
Abstract PDF
Transthyretin amyloid (ATTR) cardiomyopathy is a progressive disease caused by the infiltration of ATTR fibrils in the myocardium. Although it is a rare disease, ATTR cardiomyopathy is an important cause of heart failure with preserved ejection fraction, and its incidence is increasing due to improved diagnostic imaging tools. There has been a breakthrough in the field of transthyretin amyloidosis, which opens a new therapeutic door for the patients. In this review, an overview of tafamidis therapy in ATTR cardiomyopathy with recent results from clinical trials will be discussed.


Citations to this article as recorded by  
  • A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis
    Monali B. Patil, Piyush Ghode, Prashant Joshi
    Mini-Reviews in Medicinal Chemistry.2024; 24(6): 571.     CrossRef
  • Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
    Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn
    Diagnostics.2022; 12(3): 627.     CrossRef

CPP : Cardiovascular Prevention and Pharmacotherapy